Phase II Investigation of the Efficacy of Antimycobacterial Therapy in Chronic Pulmonary Sarcoidosis

BACKGROUND: A Phase I, single-center investigation found that 8 weeks of antimycobacterial therapy improved sarcoidosis FVC. Safety and efficacy assessments have not been performed in a multicenter cohort. RESEARCH QUESTION: The objective of this study was to determine the safety and efficacy of ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Drake, Wonder P., Culver, Daniel A., Baughman, Robert P., Judson, Marc A., Crouser, Elliott D., James, W. Ennis, Ayers, Gregory D., Ding, Tan, Abel, Kenny, Green, Abena, Kerrigan, Amy, Sesay, Ahmed, Bernard, Gordon R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American College of Chest Physicians 2021
Materias:
Diffuse Lung Disease: Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129732/
https://www.ncbi.nlm.nih.gov/pubmed/33387486
http://dx.doi.org/10.1016/j.chest.2020.12.027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129732/
https://www.ncbi.nlm.nih.gov/pubmed/33387486
http://dx.doi.org/10.1016/j.chest.2020.12.027

Ejemplares similares